Table 1.
Ref. | Pretrasplant AFP levels (ng/mL) | Importance | |
Figueras et al[19] | > 300 | Factor for mortality | |
Yao et al[16] | > 1.000 | Reduced survival | |
Bruix[20] | > 200 | Significant worse outcomes | |
Xu et al[21] | > 400 | Higher tumor recurrence | |
Mailey et al[22] | Low (≤ 20) | Mediun and high: Higher mortality | |
Mediun (20-399) | |||
High (≥ 400) | |||
Muscari et al[23] | DFS | Recurrence | |
Normal | 71% | 4% | |
10-150 | 75% | 10% | |
150-500 | 57% | 24% | |
> 500 | 46% | 62% | |
Chiao et al[24] | > 1.000 | Reason for exclusion from the WL | |
Hameed et al[25] | |||
Menon et al[26] | > 10.000 | Reason for exclusion from the WL |
AFP: Alpha fetoprotein; DFS: Disease-free survival; WL: Waiting list.